Last reviewed · How we verify
TA-7284 Low
TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion.
TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | TA-7284 Low |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors block the reabsorption of filtered glucose in the proximal tubule of the kidney, allowing excess glucose to be excreted in urine. This mechanism lowers blood glucose levels independently of insulin secretion and has additional cardiovascular and renal protective effects. TA-7284 is being developed as a treatment for type 2 diabetes mellitus.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Polydipsia
Key clinical trials
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (PHASE1)
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TA-7284 Low CI brief — competitive landscape report
- TA-7284 Low updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI